CBL-514 Clinical Trials (2026): 13 Studies for Subcutaneous Fat & Cellulite
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
13 CBL-514 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 3 indications (including Subcutaneous Fat & Cellulite) and 1,159 total planned enrollment. 2 Phase 3 CBL-514 trials and 10 Phase 2 are listed. 2 CBL-514 clinical trials are actively recruiting. Most recent activity: NCT07526974 (Oct 2027).
CBL-514 clinical trials at a glance: phase × recruitment status
| Phase | active not recruiting | completed | not yet recruiting | Total |
|---|---|---|---|---|
| P1 | 1 | 1 | ||
| P2 | 1 | 9 | 10 | |
| P3 | 2 | 2 |
Recruiting CBL-514 clinical trials (2)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07526974 | A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat ( SUPREME-02 ) | P3 | Subcutaneous Fat | 320 | Oct 2026 |
| NCT07140939 | SUPREME-01A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat | P3 | Subcutaneous Fat | 300 | Jul 2026 |
CBL-514 clinical trials by indication
Subcutaneous Fat (9)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07526974 | — | P3 | not yet recruiting | A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat ( SUPREME-02 ) |
| NCT07140939 | SUPREME-01 | P3 | not yet recruiting | A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat |
| NCT06005441 | — | P2 | completed | A Phase 2b Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat. |
| NCT05736107 | — | P2 | completed | A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat |
| NCT04897412 | — | P2 | completed | A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 2) |
| NCT05234736 | — | P2 | completed | A Study to Evaluate the Pharmacokinetic Profile of CBL-514 Injection in Healthy Volunteers |
| NCT04575467 | — | P2 | completed | A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1) |
| NCT04698642 | — | P2 | completed | A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of CBL-514 Injection for Reducing Convexity or Fullness of Abdominal Subcutaneous Fat |
| + 1 more, see All trials below. | ||||
Dercum's Disease (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06303570 | — | P2 | active not recruiting | A Study to Evaluate the Efficacy and Safety of CBL-514 Compared to Placebo in Participants With Dercum's Disease Lipomas |
| NCT05387733 | — | P2 | completed | A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With Dercum's Disease Lipomas |
Cellulite (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05836779 | — | P2 | completed | A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 2) |
| NCT05632926 | — | P2 | completed | A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 1) |
CBL-514 pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| SUPREME-01 | NCT07140939 | P3 | not yet recruiting | Subcutaneous Fat | 300 | — |
All CBL-514 trials (13)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07526974 | A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat ( SUPREME-02 ) | P3 | not yet recruiting | 320 | Caliway Biopharmaceuticals Co., Ltd. | Oct 2026 | |
| NCT07140939 | SUPREME-01 | A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat | P3 | not yet recruiting | 300 | Caliway Biopharmaceuticals Co., Ltd. | Jul 2026 |
| NCT06303570 | A Study to Evaluate the Efficacy and Safety of CBL-514 Compared to Placebo in Participants With Dercum's Disease Lipomas | P2 | active not recruiting | 19 | Caliway Biopharmaceuticals Co., Ltd. | Nov 2024 | |
| NCT06005441 | A Phase 2b Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat. | P2 | completed | 173 | Caliway Biopharmaceuticals Co., Ltd. | Nov 2023 | |
| NCT05736107 | A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat | P2 | completed | 107 | Caliway Biopharmaceuticals Co., Ltd. | May 2023 | |
| NCT05836779 | A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 2) | P2 | completed | 23 | Caliway Biopharmaceuticals Co., Ltd. | May 2023 | |
| NCT05632926 | A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 1) | P2 | completed | 12 | Caliway Biopharmaceuticals Co., Ltd. | Jan 2023 | |
| NCT05387733 | A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With Dercum's Disease Lipomas | P2 | completed | 12 | Caliway Biopharmaceuticals Co., Ltd. | Oct 2022 | |
| NCT04897412 | A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 2) | P2 | completed | 75 | Caliway Biopharmaceuticals Co., Ltd. | Feb 2022 | |
| NCT05234736 | A Study to Evaluate the Pharmacokinetic Profile of CBL-514 Injection in Healthy Volunteers | P2 | completed | 10 | Caliway Biopharmaceuticals Co., Ltd. | Feb 2022 | |
| NCT04575467 | A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1) | P2 | completed | 25 | Caliway Biopharmaceuticals Co., Ltd. | Dec 2020 | |
| NCT04698642 | A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of CBL-514 Injection for Reducing Convexity or Fullness of Abdominal Subcutaneous Fat | P2 | completed | 43 | Caliway Biopharmaceuticals Co., Ltd. | Feb 2020 | |
| NCT04699669 | A Phase 1 Study to Evaluate the Safety and Tolerability of CBL-514 Injection on Convexity or Fullness of Abdominal Subcutaneous Fat in Healthy Volunteers | P1 | completed | 40 | Caliway Biopharmaceuticals Co., Ltd. | Nov 2018 |
CBL-514 clinical trials: frequently asked questions
- How many CBL-514 clinical trials are there?
- 13 CBL-514 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 10 are marked completed.
- Are CBL-514 clinical trials recruiting in 2026?
- No active CBL-514 trials are recruiting on ClinicalTrials.gov as of the current AACT refresh. Trials may resume; this page is updated daily.
- What conditions is CBL-514 being studied for?
- CBL-514 is being studied for Subcutaneous Fat, Cellulite, Dercum's Disease. The trials are grouped by indication on this page.
- What phase is CBL-514 in?
- CBL-514 clinical trials span 2 Phase 3, 10 Phase 2, 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors CBL-514 clinical trials?
- The lead sponsor across the most CBL-514 trials is Caliway Biopharmaceuticals Co., Ltd.. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming CBL-514as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: